Abstract:Primary sclerosing cholangitis (PSC) is a devastating chronic cholestatic liver disease without effective therapy due to a limited understanding of its pathogenesis. The multidrug resistance gene 2‐knockout (Mdr2KO) mice spontaneously develop hepatobiliary injury, fibrosis, and hepatocellular carcinoma (HCC) closely resembling PSC. Previous studies have shown that accumulation of conjugated primary bile acid, such as taurocholic acid (TCA), contributes to the disease progression via activation of sphingosine‐1 phosphate receptor 2 (S1PR2)/sphingosine kinase 2 (SphK2). However, the underlying mechanisms remain to be fully identified. MicroRNAs (miRs) are small non‐coding RNAs that play essential roles in regulating various cellular pathways under both physiological and pathological conditions. The expression level of miR155 is correlated to the activation of inflammation and hepatic fibrosis. The aim of this study is to examine the role of SphK2 in bile acid‐induced cholestatic injury. Methods Wild type (WT) and Mdr2KO mice (age and gender‐matched) were treated with a specific Sphk2 inhibitor ABC294640 (50 mg/kg) by daily gavage for 4 weeks. Blood and liver tissues were collected. The serum levels of ALT, AST, and ALP levels were measured using the commercial kits. Liver tissues were processed for H&E and Masson’s trichrome staining, immunohistochemistry (IHC), and isolation of total RNA. The hepatic miR155 expression levels were analyzed using Taqman microRNA assays. The mRNA levels of the key genes involved in hepatic inflammation, fibrotic injury, and bile acid metabolism were measured by real‐time RT PCR. The protein levels of S1PR2 and SphK2 were determined by Western Blot analysis. The effect of TCA on miR155 expression in mouse cholangiocyte was determined. Results Compared to the gender/age‐matched WT mice, Mdr2 KO mice developed severe hepatobiliary injury as indicated by the upregulation of ALP, AST, and ALT, activation of the inflammatory response, and increase of liver fibrosis. The expression levels of S1PR2, SphK2, and miR155 were significantly increased in Mdr2KO mice. Treatment of ABC294640 significantly reduced hepatic macrophage infiltration, fibrotic liver injury, and expression of inflammatory mediators, including IL‐1β, MCP‐1, IL‐18, and IL‐6. In cultured mouse cholangiocytes, TCA significantly increased miR155 expression. Conclusion Bile acid‐induced activation of S1PR2/SphK2 may play critical roles in cholestatic liver fibrosis by the upreguation of miR155 and inflammatory mediators. Targeting SphK2 represents a potential therapeutic strategy for the treatment of the cholestatic liver injury. Support or Funding Information This work was supported by VA Merit Award I01BX004033 and 1I01BX001390, VA Career Scientist Award IK6BX004477 and National Institutes of Health Grant R01 DK104893 and R01DK‐057543

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Human Placental Mesenchymal Stem Cells Relieve Primary Sclerosing Cholangitis via Upregulation of TGR5 in Mdr2-/- Mice and Human Intrahepatic Cholangiocyte Organoid Models

Sphingosine kinase 2 plays a critical role in bile acid‐induced cholestatic liver injury <i>via</i> regulating miR‐155 and macrophage activation

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases

MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-β1/smad Pathway

Cholestasis alters polarization and suppressor function of hepatic regulatory T cells.

Identification of a Potential Mirna-Mrna Regulatory Network Associated with the Pathogenesis of Cholestatic Liver Diseases

Dysregulated Mir-124 and Mir-200 Expression Contribute to Cholangiocyte Proliferation in the Cholestatic Liver by Targeting IL-6/STAT3 Signalling

PPARα activation protects against cholestatic liver injury

MicroRNA‐210 Promotes Bile Acid–Induced Cholestatic Liver Injury by Targeting Mixed‐Lineage Leukemia‐4 Methyltransferase in Mice

Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

Dysregulation of Peritoneal Cavity B1a Cells and Murine Primary Biliary Cholangitis

Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways

Bile acids attenuate hepatic inflammation during ischemia/reperfusion injury

PGC‐1α is downregulated in a mouse model of obstructive cholestasis but not in a model of liver fibrosis